Teleflex Receives FDA Clearance for 150 cm Length Arrow GPSCath Balloon Dilatation Catheters

PTA balloon catheters combine angioplasty with targeted injection system in a single device for use in below the knee procedures


August 12, 2014

August 12, 2014 — Teleflex Inc.’s subsidiary Hotspur Technologies Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Arrow GPSCath Balloon Dilatation Catheters designed for use with 0.014-inch guidewires and in 150-cm length. These products enable a variety of peripheral vascular procedures to be performed below the knee with one dual-function catheter, potentially reducing procedure time, radiation dosage and expense for both patients and medical professionals.

The Arrow GPSCath Balloon Dilatation Catheter is the first dual functional balloon dilatation catheter that combines angioplasty with the proprietary VisioValve Injection System. This combination enables physicians to perform peripheral below the knee angioplasty and inject physician-selected fluids, such as contrast media, while maintaining guide wire position.

“With this latest product approval we continue our commitment to enabling medical professionals to perform peripheral access procedures that simplify and improve the doctor and patient experience while reducing health care costs,” said Benson Smith, chairman, president & CEO of Teleflex.

For more information: